FDA Peptide Tracker

Retatrutide: live FDA regulatory status

Triple GLP-1/GIP/glucagon · Investigational

The two signals

Plain-English verdict: amber.

Regulatory status: Investigational (Phase 3).

These two never collapse into one. Removal from a list is not the same as legal-to-compound, and neither is the same as available.

Availability at Peptós.LIFE

Join waitlist

What Retatrutide is

An investigational triple GLP-1/GIP/glucagon agonist posting the largest weight-loss numbers recorded so far.

The molecule the metabolic world is watching hardest.

Retatrutide is the molecule that owns the next GLP-1 headline.

Why it sits in this category

Retatrutide is tracked under Investigational. Its regulatory status is Investigational (Phase 3) — a separate signal from whether you can actually get it today. We never collapse the two.

A single molecule agonizing three receptors, GLP-1, GIP, and glucagon, combining appetite suppression with an added energy-expenditure signal from glucagon.

What it does — and what it does not do

What it does: In trials, drives the largest average body-weight reduction seen to date for the class (reported ~24–29%).

What it does not do: It is not a guaranteed result; trial figures are not a promise and grey-market product is unverified and unsafe.

What would have to change

Next milestone on the regulatory path: TRIUMPH Phase-3 readout (projected) — 2026–2027. A favorable advisory (PCAC) vote is a recommendation that leads to rulemaking — not FDA approval, not authorization to compound, and not availability.

Evidence grade

Evidence grade B — Good human evidence. large Phase-3 trial data (TRIUMPH), figures pending peer review; re-verify See our grading methodology for what each grade means.

What we still don't know: Long-term safety and durability are not yet established; the trial program is ongoing and figures may change at peer review and approval.

Regulatory timeline

Retatrutide: common questions

Is Retatrutide available in 2026?
No. Retatrutide is investigational — it is in clinical trials and has not been approved by the FDA for any use. There is no legal route to a prescription outside a trial.
Can I get Retatrutide right now?
No. Retatrutide is a status list only — join it and we will write to you if and when an approved product exists. Anything sold as Retatrutide today is not a regulated medicine.
Is Retatrutide the same as a compounded peptide?
No, and conflating them is a common error. Retatrutide is an investigational drug in a manufacturer's trial programme. Compounded peptides are prepared by a pharmacy for an individual patient under 503A. Different pathways, different rules.
What happens next for Retatrutide?
TRIUMPH Phase-3 readout (projected), 2026–2027. Trial readouts are not approvals, and approval would be the manufacturer's, not ours.

PCAC is advisory: its Jul 2026 recommendation leads to rulemaking, not instant availability. A favorable advisory vote is a recommendation, not FDA approval or authorization to compound. Realistic earliest legitimate access is late 2026 into 2027. Reclassification is not the same as FDA approval. Compounded medications are not evaluated or approved by the FDA for safety, efficacy, or quality, where that applies, we say so, plainly.

Primary source: FDA source record

See the full status board or this molecule's knowledge-base monograph.

Embed this card on your site · free, CC BY 4.0, no key.

Last updated July 26, 2026 · Peptós.LIFE · Not medical advice.